Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Pancreas Neoplasms
About this trial
This is an interventional prevention trial for Pancreas Neoplasms focused on measuring celecoxib for pancreas lesions
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of IPMN ECOG Performance status of 0, 1, or 2 Adequate liver function, bilirubin < 1.5 times ULN, ALT or AST < 2.5 times ULN Adequate renal function: creatinine < 1.8 Must be at least 18 Exclusion Criteria: Use of COX-2 selective inhibitors within the last month More than occasional use of NSAIDS in last month (occasional use defined as up to twice weekly dosing) CA19-9 levels 1.5 times the ULN Active pancreatitis Taking sulphonylureas, fluconazole or lithium concomitantly
Sites / Locations
- Indiana University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Surgical Candidate
Medical Candidate
COX-2 Inhibitor 6-8 weeks prior to surgery
COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP